SCHEMBL25027702

SCHEMBL25027702

NC(=O)c1cc2c(Cl)ccnc2cc1OC1CCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 13/20 0.50
MKNK1 Q9BUB5 2/20 0.46
MKNK2 Q9HBH9 2/20 0.46
RET P07949 2/20 0.45
PDGFRB P09619 2/20 0.45
KIT P10721 2/20 0.45
FGFR1 P11362 2/20 0.45
PDGFRA P16234 2/20 0.45
FLT1 P17948 2/20 0.45
FLT4 P35916 2/20 0.45
KDR P35968 2/20 0.45
RIPK2 O43353 1/20 0.45
ERN1 O75460 1/20 0.45
STK10 O94804 1/20 0.45
MAP3K6 O95382 1/20 0.45
ABL1 P00519 1/20 0.45
ESR1 P03372 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
BCR P11274 1/20 0.45
NQO2 P16083 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25166319 0.85 IRAK4 (0.50) IRAK4RETPDGFRBKITFGFR1
SCHEMBL25029414 0.85 IRAK4 (0.50) IRAK4RETPDGFRBKITFGFR1
SCHEMBL1323767 0.81 KDR (0.56) IRAK4RETPDGFRBKITFGFR1
SCHEMBL31218187 0.81 KDR (0.56) IRAK4RETPDGFRBKITFGFR1
SCHEMBL6005264 0.80 MET (0.47) IRAK4MKNK1MKNK2RETPDGFRB
SCHEMBL27104752 0.79 IRAK4 (0.51) IRAK4MKNK1MKNK2RETPDGFRB
SCHEMBL25166365 0.78 KDR (0.41) IRAK4RETPDGFRBKITFGFR1
SCHEMBL22965528 0.78 TDP1 (0.43) IRAK4RETPDGFRBKITFGFR1
SCHEMBL25029424 0.78 KDR (0.43) IRAK4MKNK1MKNK2RETPDGFRB
SCHEMBL21201011 0.77 KDR (0.44) IRAK4RETPDGFRBKITFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912663-B2 Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses SHANGHAI AB PHARMATECH LTD. (CN) 2024-02-27 US disclosed
US-11912663-B2 Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses SHANGHAI AB PHARMATECH LTD. (CN) 2024-02-27 US disclosed
US-20230124784-A1 MULTI-TARGETED TYROSINE KINASE INHIBITORS AND THEIR PHARMACEUTICAL USES SHANGHAI AB PHARMATECH LTD. (CN) 2023-04-20 US disclosed
WO-2023016543-A1 UREA MULTI-TARGET TYROSINE KINASE INHIBITOR AND MULTIPLE MEDICAL APPLICATIONS THEREOF 上海爱博医药科技有限公司 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912663-B2 Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses ABL1, ERBB2, RET IRAK4 994/4885MKNK1 291/4885MKNK2 302/4885
US-20230124784-A1 MULTI-TARGETED TYROSINE KINASE INHIBITORS AND THEIR PHARMACEUTICAL USES ABL1, ERBB2, RET IRAK4 994/4885MKNK1 291/4885MKNK2 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.